Differential Effects of Vasopressin and Oxytocin on Attention Control

January 20, 2021 updated by: Keith Kendrick, University of Electronic Science and Technology of China

The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Study Overview

Status

Completed

Conditions

Detailed Description

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Chengdu
      • Sichuan, Chengdu, China, 611731
        • University of Electronic Science and Technology of China (UESTC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male, healthy participants
  • Non smokers

Exclusion Criteria:

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Placebo intranasally
Administration of placebo intranasally
Experimental: Vasopressin
Vasopressin (20IU) intranasally
Administration of vasopressin (20IU) intranasally
Experimental: Oxytocin
Oxytocin (24IU) intranasally
Administration of oxytocin (24IU) intranasally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli
Time Frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Time Frame: 45 minutes - 100 minutes after treatment
Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli
Time Frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions
Time Frame: 45 minutes - 100 minutes after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions
Time Frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Time Frame: 45 minutes - 100 minutes after treatment
Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade error rates for the separate facial emotions
Time Frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin, oxytocin and placebo treatment conditions
Time Frame: 45 minutes - 100 minutes after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Keith Kendrick, PhD, University of Electronic Science and Technology of China (UESTC)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 19, 2017

Primary Completion (Actual)

January 1, 2021

Study Completion (Actual)

January 1, 2021

Study Registration Dates

First Submitted

January 14, 2021

First Submitted That Met QC Criteria

January 14, 2021

First Posted (Actual)

January 20, 2021

Study Record Updates

Last Update Posted (Actual)

January 22, 2021

Last Update Submitted That Met QC Criteria

January 20, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Oxytocin

3
Subscribe